Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 9/20 | 0.95 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.76 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.74 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.74 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.71 |
| ▸ | F3 | P13726 | 1/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.70 |
| ▸ | P4HB | P07237 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25189030 | 1.00 | CXCL12 (0.95) | CXCL12TNFRSF1ACXCR4NFE2L2CALM1 | |
| SCHEMBL25206969 | 1.00 | CXCL12 (0.95) | CXCL12TNFRSF1ACXCR4NFE2L2CALM1 | |
| SCHEMBL9643457 | 0.97 | CXCL12 (1.00) | CXCL12TNFRSF1ACXCR4CALM1MKNK2 | |
| SCHEMBL9643460 | 0.97 | CXCL12 (1.00) | CXCL12TNFRSF1ACXCR4CALM1MKNK2 | |
| SCHEMBL30384490 | 0.92 | CXCL12 (0.89) | CXCL12CXCR4NFE2L2 | |
| SCHEMBL25193952 | 0.92 | CXCL12 (0.89) | CXCL12CXCR4NFE2L2 | |
| SCHEMBL12677857 | 0.92 | CXCL12 (0.89) | CXCL12CXCR4NFE2L2 | |
| SCHEMBL25198557 | 0.89 | CAPN1 (0.81) | CXCL12CXCR4 | |
| SCHEMBL15691794 | 0.89 | CXCL12 (0.76) | CXCL12CXCR4CALM1 | |
| SCHEMBL30382735 | 0.89 | CXCL12 (0.76) | CXCL12CXCR4CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716532-B2 | One pot multicomponent synthesis of some novel hydroxy stilbene derivatives with alpha, beta-carbonyl conjugation under microwave irradiation | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2014-05-06 | — | — | US | disclosed |
| US-20120165567-A1 | ONE POT MULTICOMPONENT SYNTHESIS OF SOME NOVEL HYDROXY STILBENE DERIVATIVES WITH ALPHA, BETA-CARBONYL CONJUGATION UNDER MICROWAVE IRRADIATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2012-06-28 | — | — | US | disclosed |
| WO-2010113005-A2 | ONE POT MULTICOMPONENT SYNTHESIS OF SOME NOVEL HYDROXY STILBENE DERIVATIVES WITH ALPHA, BETA-CARBONYL CONJUGATION UNDER MICROWAVE IRRADIATION | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165567-A1 | ONE POT MULTICOMPONENT SYNTHESIS OF SOME NOVEL HYDROXY STILBENE DERIVATIVES WITH ALPHA, BETA-CARBONYL CONJUGATION UNDER MICROWAVE IRRADIATION | SIK1, SIK2, HCK | CXCL12 1604/4885TNFRSF1A 2599/4885CXCR4 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.